Senseonics (NYSE: SENS) has launched its first clinical study of a transmitter-free version of its Eversense 365 continuous glucose monitor.
This targeted approach could offer a way to prevent the recurrence of aggressive brain tumors.
The regulatory clearance brings Coreline Soft’s total to 13 FDA 510(k) clearances and broadens its chest AI portfolio.
The LoopGo integrates the monitoring unit directly into an adjustable arm cuff, eliminating external tubes and cabling.
Elucid recently received FDA clearance for its AI-powered FFR-IQ software, which provides a noninvasive estimate of fractional flow reserve from coronary CT angiography.